KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Interest & Investment Income (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Interest & Investment Income data on record, last reported at $2.3 million in Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 58.69% year-over-year to $2.3 million; the TTM value through Dec 2025 reached $22.7 million, up 15.46%, while the annual FY2025 figure was $22.7 million, 15.46% up from the prior year.
  • Interest & Investment Income reached $2.3 million in Q4 2025 per PCRX's latest filing, down from $8.5 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $8.5 million in Q3 2025 and bottomed at $80000.0 in Q4 2021.
  • Average Interest & Investment Income over 5 years is $3.0 million, with a median of $2.8 million recorded in 2022.
  • Peak YoY movement for Interest & Investment Income: crashed 88.44% in 2021, then soared 3381.25% in 2022.
  • A 5-year view of Interest & Investment Income shows it stood at $80000.0 in 2021, then skyrocketed by 3381.25% to $2.8 million in 2022, then grew by 22.98% to $3.4 million in 2023, then skyrocketed by 62.19% to $5.6 million in 2024, then plummeted by 58.69% to $2.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest & Investment Income were $2.3 million in Q4 2025, $8.5 million in Q3 2025, and $5.0 million in Q2 2025.